EP0742794A1 - Interleukin-6 (il-6) antagonists - Google Patents

Interleukin-6 (il-6) antagonists

Info

Publication number
EP0742794A1
EP0742794A1 EP95940401A EP95940401A EP0742794A1 EP 0742794 A1 EP0742794 A1 EP 0742794A1 EP 95940401 A EP95940401 A EP 95940401A EP 95940401 A EP95940401 A EP 95940401A EP 0742794 A1 EP0742794 A1 EP 0742794A1
Authority
EP
European Patent Office
Prior art keywords
seq
interleukin
sil
receptor
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95940401A
Other languages
German (de)
French (fr)
Inventor
Gennaro Ciliberto
Carlo Toniatti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Publication of EP0742794A1 publication Critical patent/EP0742794A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to the field of immunology. More specifically, the subject of the present invention are mutants- of the soluble forms of receptor ⁇ of interleukin 6 that interfere in a negative manner in the formation of the dimeric receptor complex between the monomeric receptor complex IL-6/sIL-6R ⁇ and gp 130. A further subject of the invention is the use of these mutants as interleukin-6 antagonists to control, prevent and treat the diseases caused by abnormal IL-6 activity.
  • Interleukin-6 elicits a variety of biological responses on different target cells. However - while the physiological production of IL-6 regulates B-cells proliferation and maturation, T-cell activation and the production of acute-phase proteins in liver during inflammatory response - disregulated production of the cytokine plays a crucial role in the pathogenesis of many inflammatory, autoimmune and neoplastic diseases.
  • IL-6 the mature human IL-6 protein
  • h IL-6 is a 185 a ino acid polypeptide containing two disulfide bonds (Cys 45 - Cys 51, and Cys 74 - Cys 84) .
  • IL-6 functions through interaction of two binding sites (known as site I and site II) with at least two specific receptors (IL-R ⁇ and gp 130) on the surface of the target cells, creating a trimeric complex IL-6- (receptor) 2 .
  • This complex is formed sequentially: a first receptor (IL-6R ⁇ ) binds with low affinity to site I of IL-6 without transmitting the signal; subsequently a second receptor (gp 130) , after binding with high affinity to site II of IL-6, transduces the signal.
  • a first receptor IL-6R ⁇
  • gp 130 second receptor
  • hIL-6 mutants have been designed that are capable of binding a first receptor to site I, but incapable of dimerising the receptor because of mutations that sterically inhibit binding of the second receptor to site II. Mutants of this type have been described in WO 94/09138 (Cetus Oncology Corporation), and WO 94/011402 and PCT/IT 94/00095 (Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A. ) .
  • soluble forms of the receptor ⁇ of IL-6 (sIL-6R ⁇ ) containing one or more mutations in the region interfacing with gp 130 are antagonists of interleukin 6.
  • sIL-6Rct contains at least one mutation in a position chosen from Ala 228, Asn 230, His 280 and Asp 281.
  • the mutations may, for example, be chosen from the group comprising: Asn230Asp (SEQ ID NO:l); Ala228Asp/Asn230Asp (SEQ ID NO:2); His280Ser/Asp281Val (SEQ ID NO:3).
  • sIL-6R ⁇ contains multiple mutations in positions Ala 228, Asn 230, His 280 and Asp 281.
  • a multiple mutation that has given good results is Ala228Asp/Asn230Asp/His280Ser/Asp281Val (SEQ ID NO:4).
  • the antagonists of IL-6 which according to the invention consist of soluble forms of the receptor ⁇ of IL-6, mutated in the interface that binds to gp 130, can be administered at concentrations therapeutically effective for the treatment and prevention of diseases related to abnormal IL-6 activity.
  • the antagonists according to the invention are administered preferably by endovenous and/or subcutaneous injection. Experts in the field are well acquainted with these methods of administration.
  • Figure 1A shows resolution on SDS/PAGE gel (12%), in vitro, of the co-immunoprecipitates of mutants according to the invention with sgp 130 (soluble form of gp 130) marked using 35 S.
  • Figure IB shows the position on the gel corresponding to the migrated 125 I-IL-6.
  • Figure 2 shows, in the form of a histogram, the different capacities of the wild type sIL-6R ⁇ receptor and the sIL-6R ⁇ receptors mutated to interact with gp 130 on the membrane of A 375 cells.
  • Figure 3 shows resolution on SDS/PAGE gel (12%), in vitro, of the co-immunoprecipates of sgp 130 marked with 35 S or with 2.0 ⁇ g of wild receptor or with 2.0 ⁇ g of mutant receptor (SEQ ID NO: 4) .
  • Figure 4 shows the antagonist activity of the mutant SEQ ID NO: 4 on HepG2 cells in comparison with the agonistic properties of wild type shIL-6R ⁇ .
  • Figure 5 shows resolution on gel of the complex formed by APRF with the DNA binding site (SIE, Serum Inducible Element) .
  • SIE Serum Inducible Element
  • Antagonists of IL- ⁇ according to the invention may be produced synthetically or using recombinant techniques.
  • the cDNA coding for sIL- 6R ⁇ can be incorporated in a plasmid before being expressed in procaryotic or eukaryotic cells. Bacteria are the preferred procaryotic microorganisms.
  • the cDNA coding for the sIL-6R ⁇ mutants according to the invention can be introduced into mammal cells: these mammal cells can be chosen from the group comprising CHO, COS, C127, HepG2, SK Hep.
  • the protein can also be expressed in insect cells (Sf9 or HighFive) using the well known recombinant Baculovirus technology (AcNPV strain) .
  • Baculovirus technology Baculovirus technology
  • Example 1 Preparation of sIL-6R ⁇ mutants sIL-6R ⁇ cDNA was obtained as a 5'EcoRI-3'XbaI fragment by PCR using the IL-6R ⁇ complete cDNA as template (Sporeno E., Paonessa G., Salvati A.L., Graziani R., Delmastro P., Ciliberto G. and Toniatti C. (1994) J. Biol. Chem. 269, 10991-10995).
  • the 3' primer was designed in order to introduce an artificial TAG stop codon at amino acid position 324 preceded by a six- histidine coding sequence. This was done to ensure that the sIL-6R ⁇ and the mutants thereof produced by us have a six histidine "tail" at the carboxy-terminal end of the molecule, which can be useful for purification of the molecule using metal affinity chromatography.
  • the fragment generated was then introduced into the COS-7 cells expression vector pcDNAI (Invitrogen) and sequenced in its entirety, thus obtaining plas id pC6FRH.
  • Plasmid pC ⁇ FRH was in turn used as a template to obtain constructs coding for the following four mutants: Asn230Asp (SEQ ID NO: 1); Asn230Asp/Ala228Asp (SEQ ID NO: 2); His280Ser/Asp281Val (SEQ ID NO 3) and Ala228Asp/Asn230Asp/His280Ser/Asp281Val (SEQ ID NO: 4), by a two-step PCR as described in the past (Landt 0., Grunert H.P., and Hahn, U. (1990) Gene 96, 125-128).
  • the mutants were then expressed in COS-7 cells.
  • the COS-7 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% FCS, plus glutamine and antibiotics, at 5% CO:.
  • 2.5xl0 6 COS-7 cells were seeded in 100-mm tissue culture dishes and the next day transfected with 2 ⁇ g of the various shIL-6R ⁇ expression vectors using the DEAE-dextran technique as described in Seed B., Aruffo A. (1987) Proc. Natl. Acad. Sci. USA 84, 3365- 3369. 16 h after transfection cells were split, replated in 100-mm dishes and grown in complete medium at 37°C.
  • Ala228Asp/Asn230Asp (SEQ ID NO : 2 ) 2 . 0 ⁇ 1 His280Ser/Asp281Val ( SEQ ID NO : 3 ) 4 . 3 ⁇ 2 Ala228Asp/Asn230Asp/ His280Ser/Asp281Val ( SEQ ID NO : 4 ) 2 . 5 ⁇ 1 wild type sIL-6R ⁇ 2 . 0 ⁇ 1
  • IL-6-dependent formation of sIL-6R ⁇ /sgpl30 heterodimers can be easily monitored in vi tro by co- immunoprecipitations with the use of suitable monoclonal antibodies.
  • a selection was therefore made of the mutants showing an IL-6 binding affinity in the same order of magnitude as the wild-type and their binding to sgpl30 was evaluated by co-immunoprecipitation in the presence of IL-6.
  • 35 S-labelled sgp 130 was incubated with 125 I-IL-6 (as an internal standard for the immunoprecipitation) and aliquots of transfected COS-7 cell culture medium, containing either native or mutant receptors.
  • the receptor mutants were also tested for their ability to interact with gpl30 on the cell surface.
  • binding experiments were performed on human melanoma A375 cells which have an excess of gpl30 molecules over IL-6R ⁇ .
  • binding of 125 I-IL-6 to A375 monolayers could be strongly enhanced by addition of the soluble receptor.
  • This phenomenon is due to the ability of the sIL-6R ⁇ to bind 125 I-IL-6 and subsequently to interact with the gpl30 molecules present on the surface of the cells.
  • the specificity of this interaction is demonstrated by the fact that the increased binding of 125 I-IL-6 in the presence of sIL- 6R ⁇ is competed by the addition of an excess of unlabeled human Oncostatin M (OM) (fig.
  • OM Oncostatin M
  • this mutant to be the one that, without any decrease in the affinity for IL-6, has the greatest effect on gpl30 binding.
  • its production and that of the wild type soluble receptor was scaled up using the MaxBac® system (Invitrogen' s Baculovirus Expression System) .
  • the expressed and purified receptors were tested in immunoprecipitation experiments.
  • Sf9 cells grown in Grace's insect medium, were used for transfection of transfer vectors, isolation of recombinant virus and preparation of high-titer virus stocks.
  • High Five® cells (Invitrogen) were instead used for production of proteins. Briefly, 4xl0 7 High Five® cells, grown in complete Grace's insect medium, were seeded into 750 ml flasks and infected with the appropriate recombinant virus at a MOI of 10. After 2 hours, cells were washed and SF-900 serum-free medium was added. The culture supernatants were harvested at 36 hours post-infection, dialyzed against PBS and directly loaded on a Ni 2+ -NTA-agarose column.
  • both wild type shIL-6R ⁇ and mutant were eluted in PBS/80 mM imidazole. Purified protein was dialyzed against PBS and directly used or stored at 4°C for up to three weeks.
  • APRF Acute Phase Response Factor
  • the mutant was added to HepG2 cells induced with the IL-6- related cytokine OM, which is also known to efficiently induce APRF phosphorylation. As shown in figure 5, the mutant did not antagonize OM activity. - -
  • MOLECULE TYPE protein
  • HYPOTHETICAL no
  • MOLECULE TYPE protein
  • HYPOTHETICAL no
  • NAME Ala228Asp/Asn230Asp/His280Ser/Asp281Val
  • IDENTIFICATION METHOD Electrophoresis on a denaturing SDS/polyacrylamide gel
  • D OTHER INFORMATION: amino acid sequence of a mutant form of the interleukin 6 receptor from position 222 to position 287.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

These are antagonists of interleukin-6, characterised in that they consist of soluble forms of the receptor α of human IL-6 (shIL-6Rα) containing one or more mutation in the gp130 binding interface. In a preferred embodiment, the mutations are present in a position chosen from the group comprising Ala 228, Asn 230, His 280 and Asp 281. These antagonists can be used as agents capable of preventing and treating diseases caused by abnormal IL-6 activity. The figure shows the antagonist activity of the mutant Ala228Asp/Asn 230Asp/His280Ser/Asp281Val in comparison with the agonist properties of wild type shIL-6Rα. This antagonist can be used for preparation of drugs for the prevention, control and treatment of diseases caused by abnormal IL-6 bioactivity.

Description

INTERLEUKIN-6 (IL-6) ANTAGONISTS
DESCRIPTION The present invention relates to the field of immunology. More specifically, the subject of the present invention are mutants- of the soluble forms of receptor α of interleukin 6 that interfere in a negative manner in the formation of the dimeric receptor complex between the monomeric receptor complex IL-6/sIL-6Rα and gp 130. A further subject of the invention is the use of these mutants as interleukin-6 antagonists to control, prevent and treat the diseases caused by abnormal IL-6 activity. The term "interleukin 6" or "IL-6", in the context of the present invention, means IL-6 and fragments, deletions, insertions, substitutions, mutations and modifications thereof that maintain the biological characteristics of wild IL-6. Unless otherwise specified, the term refers to human IL-6.
Interleukin-6 elicits a variety of biological responses on different target cells. However - while the physiological production of IL-6 regulates B-cells proliferation and maturation, T-cell activation and the production of acute-phase proteins in liver during inflammatory response - disregulated production of the cytokine plays a crucial role in the pathogenesis of many inflammatory, autoimmune and neoplastic diseases.
As is known from the state of the art, various attempts have been made to perfect IL-6 bioactivity inhibitors, both in order to study the role played by this cytokine in the genesis of single diseases, and in order to define drugs for treatment.
It is also known that the mature human IL-6 protein (h IL-6) is a 185 a ino acid polypeptide containing two disulfide bonds (Cys 45 - Cys 51, and Cys 74 - Cys 84) . IL-6 functions through interaction of two binding sites (known as site I and site II) with at least two specific receptors (IL-Rα and gp 130) on the surface of the target cells, creating a trimeric complex IL-6- (receptor)2. This complex is formed sequentially: a first receptor (IL-6Rα) binds with low affinity to site I of IL-6 without transmitting the signal; subsequently a second receptor (gp 130) , after binding with high affinity to site II of IL-6, transduces the signal.
Based on this mechanism, hIL-6 mutants have been designed that are capable of binding a first receptor to site I, but incapable of dimerising the receptor because of mutations that sterically inhibit binding of the second receptor to site II. Mutants of this type have been described in WO 94/09138 (Cetus Oncology Corporation), and WO 94/011402 and PCT/IT 94/00095 (Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A. ) .
It has now surprisingly been found, and this discovery forms the basis of the present invention, that soluble forms of the receptor α of IL-6 (sIL-6Rα) containing one or more mutations in the region interfacing with gp 130 are antagonists of interleukin 6.
In one embodiment, sIL-6Rct contains at least one mutation in a position chosen from Ala 228, Asn 230, His 280 and Asp 281. The mutations may, for example, be chosen from the group comprising: Asn230Asp (SEQ ID NO:l); Ala228Asp/Asn230Asp (SEQ ID NO:2); His280Ser/Asp281Val (SEQ ID NO:3).
In a preferred embodiment, sIL-6Rα contains multiple mutations in positions Ala 228, Asn 230, His 280 and Asp 281. A multiple mutation that has given good results is Ala228Asp/Asn230Asp/His280Ser/Asp281Val (SEQ ID NO:4).
The antagonists of IL-6, which according to the invention consist of soluble forms of the receptor α of IL-6, mutated in the interface that binds to gp 130, can be administered at concentrations therapeutically effective for the treatment and prevention of diseases related to abnormal IL-6 activity. For this purpose, the antagonists according to the invention are administered preferably by endovenous and/or subcutaneous injection. Experts in the field are well acquainted with these methods of administration.
Up to this point a general description of the invention has been given. A more detailed description of the invention will now be provided, with the aid of the following examples, in order to give a clearer understanding of the objects, characteristics, advantages and operating methods thereof.
Figure 1A shows resolution on SDS/PAGE gel (12%), in vitro, of the co-immunoprecipitates of mutants according to the invention with sgp 130 (soluble form of gp 130) marked using 35S. Figure IB shows the position on the gel corresponding to the migrated 125I-IL-6.
Figure 2 shows, in the form of a histogram, the different capacities of the wild type sIL-6Rα receptor and the sIL-6Rα receptors mutated to interact with gp 130 on the membrane of A 375 cells.
Figure 3 shows resolution on SDS/PAGE gel (12%), in vitro, of the co-immunoprecipates of sgp 130 marked with 35S or with 2.0 μg of wild receptor or with 2.0 μg of mutant receptor (SEQ ID NO: 4) . Figure 4 shows the antagonist activity of the mutant SEQ ID NO: 4 on HepG2 cells in comparison with the agonistic properties of wild type shIL-6Rα.
Figure 5 shows resolution on gel of the complex formed by APRF with the DNA binding site (SIE, Serum Inducible Element) . (The mutant SEQ ID NO: 4 does not inhibit activation of OM-dependent APRF on HepG2 cells) .
Antagonists of IL-β according to the invention may be produced synthetically or using recombinant techniques. In the latter case the cDNA coding for sIL- 6Rα can be incorporated in a plasmid before being expressed in procaryotic or eukaryotic cells. Bacteria are the preferred procaryotic microorganisms. Alternatively, the cDNA coding for the sIL-6Rα mutants according to the invention can be introduced into mammal cells: these mammal cells can be chosen from the group comprising CHO, COS, C127, HepG2, SK Hep. Furthermore, the protein can also be expressed in insect cells (Sf9 or HighFive) using the well known recombinant Baculovirus technology (AcNPV strain) . Example 1 Preparation of sIL-6Rα mutants sIL-6Rα cDNA was obtained as a 5'EcoRI-3'XbaI fragment by PCR using the IL-6Rα complete cDNA as template (Sporeno E., Paonessa G., Salvati A.L., Graziani R., Delmastro P., Ciliberto G. and Toniatti C. (1994) J. Biol. Chem. 269, 10991-10995). The 3' primer was designed in order to introduce an artificial TAG stop codon at amino acid position 324 preceded by a six- histidine coding sequence. This was done to ensure that the sIL-6Rα and the mutants thereof produced by us have a six histidine "tail" at the carboxy-terminal end of the molecule, which can be useful for purification of the molecule using metal affinity chromatography. The fragment generated was then introduced into the COS-7 cells expression vector pcDNAI (Invitrogen) and sequenced in its entirety, thus obtaining plas id pC6FRH. Plasmid pCβFRH was in turn used as a template to obtain constructs coding for the following four mutants: Asn230Asp (SEQ ID NO: 1); Asn230Asp/Ala228Asp (SEQ ID NO: 2); His280Ser/Asp281Val (SEQ ID NO 3) and Ala228Asp/Asn230Asp/His280Ser/Asp281Val (SEQ ID NO: 4), by a two-step PCR as described in the past (Landt 0., Grunert H.P., and Hahn, U. (1990) Gene 96, 125-128).
The mutants were then expressed in COS-7 cells. For this purpose, the COS-7 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% FCS, plus glutamine and antibiotics, at 5% CO:. For protein expression, 2.5xl06 COS-7 cells were seeded in 100-mm tissue culture dishes and the next day transfected with 2 μg of the various shIL-6Rα expression vectors using the DEAE-dextran technique as described in Seed B., Aruffo A. (1987) Proc. Natl. Acad. Sci. USA 84, 3365- 3369. 16 h after transfection cells were split, replated in 100-mm dishes and grown in complete medium at 37°C. After 72-96 h the medium was collected, centrifuged and used for co-immunoprecipitation experiments and binding analysis. To monitor the expression level of each mutant, 2.5xl05 transfected COS-7 cells were replated in 35-mm dishes and, 48 h after transfection, metabolically labeled with [35S]methionine for 4h. The supernatants were i munoprecipitated with anti-human IL-6Rα monoclonal antibody I6R1/9.G11. The immunoprecipitated material was then analyzed by electrophoresis through a polyacrylamide gel containing SDS.
IL-6 binding analysis of mutants
To determine the affinity for IL-6 of the sIL-6Rα mutants contained in the conditioned COS cells culture medium, the six-histidine "tail" in the -proteins produced by us was used.
Appropriate amounts of transfected COS cells supernatant, previously determined in titration experiments and to which imidazole was added up to a final concentration of 5 M, were mixed with 20-40 pM 125I-IL-6 and increasing concentrations of unlabeled cytokine. At equilibrium conditions, 40 μl of Ni:*-NTA- Agarose (Quiagen) , a resin capable of selectively binding proteins containing histidine "tails", was added and incubation prolonged for one additional hour. The ligand bound by the receptor and, therefore, indirectly resin-associated, was separated from free ligand
(supernatant) by centrifugation through a cushion of 30* sucrose in PBS. All steps were performed at 4°C. The values of free and bound cp (radioactivity count per minute) allowed drawing of competition displacement curves. The apparent Kd of the various soluble IL-6 receptors was determined after Scatchard transformation of the results (see the article by Sporeno, Paonessa,
Salviati, Graziani, Delmastro, Ciliberto and Toniatti
(1994), J. Biol. Chem. 269, 10991-10995) . Analysis of binding data and curve fitting was done using the UltraFit software (Biosoft®) on a Macintosh computer.
As can be seen from Table 1, the binding affinity:
1) remains substantially unprejudiced for mutants Asn230Asp (SEQ ID NO: 1), Asn230Asp/Ala228Asp (SEQ ID NO:
2) ; b) is reduced in a slight but reproducible manner (between 2.5 nM and 6 nM) for His280Ser/Asp281Val (SEQ ID
NO: 3) ; and c) the activity of the wild type form is fully maintained for the mutant Ala228Asp/Asn230Asp/His280Ser/Asp281Val (SEQ ID NO: 4) .
TABLE 1
IL-6 binding affinity of soluble interleukin 6 receptor (wild and mutated) , labeled with histidine and expressed in COS cells
Mutant IL-6 binding affinity
nM
Asn230Asp ( SEQ ID NO : 1 ) 1 . 5 ± 1
Ala228Asp/Asn230Asp (SEQ ID NO : 2 ) 2 . 0 ± 1 His280Ser/Asp281Val ( SEQ ID NO : 3 ) 4 . 3 ± 2 Ala228Asp/Asn230Asp/ His280Ser/Asp281Val ( SEQ ID NO : 4 ) 2 . 5 ± 1 wild type sIL-6Rα 2 . 0 ± 1
Binding of mutants to gp!30
The IL-6-dependent formation of sIL-6Rα/sgpl30 heterodimers can be easily monitored in vi tro by co- immunoprecipitations with the use of suitable monoclonal antibodies. A selection was therefore made of the mutants showing an IL-6 binding affinity in the same order of magnitude as the wild-type and their binding to sgpl30 was evaluated by co-immunoprecipitation in the presence of IL-6. 35S-labelled sgp 130 was incubated with 125I-IL-6 (as an internal standard for the immunoprecipitation) and aliquots of transfected COS-7 cell culture medium, containing either native or mutant receptors. After in vitro binding, anti IL-6Rα mAb I6/R19.G11 was added to the mixtures and the immunoprecipitates resolved on SDS/PAGE gels. The results are shown in figure 1. As can be seen, the mutant His280Ser/Asp281Val (SEQ ID NO: 3) strongly reduced the association of the IL-6/ sIL-6Rα complex sgp 130 molecule (lane 4) . Also the single substitution mutant Asn230Asp (SEQ ID NO: 1) had decreased interaction with sgpl30 (lane 2) . The effect of this mutant on interaction with sgp 130 is of the same magnitude as that of mutant Ala228Asp/Asn230Asp (SEQ ID NO: 2) . Finally, the quadruple mutant Ala228Asp/Asn230Asp/His280Ser/Asp281Val (SEQ ID NO: 4) displayed the lowest ability to co-i munoprecipitate 35S- gp 130 (lane 5) .
The receptor mutants were also tested for their ability to interact with gpl30 on the cell surface. For this purpose, binding experiments were performed on human melanoma A375 cells which have an excess of gpl30 molecules over IL-6Rα. In fact, binding of 125I-IL-6 to A375 monolayers could be strongly enhanced by addition of the soluble receptor. This phenomenon is due to the ability of the sIL-6Rα to bind 125I-IL-6 and subsequently to interact with the gpl30 molecules present on the surface of the cells. The specificity of this interaction is demonstrated by the fact that the increased binding of 125I-IL-6 in the presence of sIL- 6Rα is competed by the addition of an excess of unlabeled human Oncostatin M (OM) (fig. 2) . This cytokine is able to bind directly to gpl30 and to compete the binding of the IL-6/IL-6Rα complex with gpl30. Unlike wild type shIL-6Rα, only a minor increase in specific binding was detected when cells were challenged with 125I-IL-6 plus the soluble mutant receptors acting as antagonists (figure 2) . The greatest disturbance to interaction with gpl30 is shown by the mutants His280Ser/Asp281Val (SEQ ID NO: 3) and Ala228Asp/Asn230Asp/His280Ser/Asp281Val (SEQ ID NO: 4) . Demonstration that the mutant Ala228Asp/Asn230Asp/ His280Ser/Asp281Val (SEQ ID NO: 4) is an IL-6 antagonist
The results shown above indicate this mutant to be the one that, without any decrease in the affinity for IL-6, has the greatest effect on gpl30 binding. In order to study the biological activity of this mutant, its production and that of the wild type soluble receptor was scaled up using the MaxBac® system (Invitrogen' s Baculovirus Expression System) . The expressed and purified receptors were tested in immunoprecipitation experiments.
Sf9 cells, grown in Grace's insect medium, were used for transfection of transfer vectors, isolation of recombinant virus and preparation of high-titer virus stocks. High Five® cells (Invitrogen) were instead used for production of proteins. Briefly, 4xl07 High Five® cells, grown in complete Grace's insect medium, were seeded into 750 ml flasks and infected with the appropriate recombinant virus at a MOI of 10. After 2 hours, cells were washed and SF-900 serum-free medium was added. The culture supernatants were harvested at 36 hours post-infection, dialyzed against PBS and directly loaded on a Ni2+-NTA-agarose column. After washing steps with PBS/8 mM imidazole, both wild type shIL-6Rα and mutant were eluted in PBS/80 mM imidazole. Purified protein was dialyzed against PBS and directly used or stored at 4°C for up to three weeks.
The use of purified proteins made it possible to quantify the amount of receptor and to compare the ability of wild type receptor and mutant receptor to interact with sgpl30 in the presence of a wide range of IL-6 concentrations. The results (figure 3) were in good agreement with those previously obtained with COS cell- derived receptors. Interestingly at each point of the curve the amount of co-immunoprecipitated gpl30 is lower for the mutant receptor than for the wild type receptor and this is true even at the highest concentrations of the cytokine tested (100 nM) . These findings confirm that the interaction between IL-6 and mutant sIL-6Rα generates a complex with lower affinity for gpl30.
To test the potential antagonism of the mutant for IL-6 activity, we chose the IL-6 dependent activation of transcription factor APRF (Acute Phase Response Factor) /STAT 3 in human hepatoma cells. Activation of APRF, which is dependent on tyrosine phosphorylation, is a rapid cytoplasmic event which takes place within minutes of stimulation with all cytokines of the IL-6 family.
Human HepG2 cells were stimulated with increasing concentrations of IL-6 together with a fixed amount of wild type and mutant receptors (100 nM) . As shown in figure 4, while shIL-6Rα potentiated APRF induction by IL-6 (compare lanes 2-4 and 5-7 in figure 4), the soluble mutant receptor not only lacked any agonistic activity but instead down-modulated the activity of the cytokine
(figure 4, lanes 8-10) . As predicted from the co- immunoprecipitation experiments, the inhibition was complete when cells were treated with up to 20 pM IL-β
(lanes 8 and 9, figure 4) and only a weak induction was detected at the highest concentration of IL-6 (200 pM, lane 10 of figure 4) .
To test if antagonism was specific for IL-6, the mutant was added to HepG2 cells induced with the IL-6- related cytokine OM, which is also known to efficiently induce APRF phosphorylation. As shown in figure 5, the mutant did not antagonize OM activity. - -
SEQUENCE LISTING GENERAL INFORMATION (i) APPLICANT: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.p.A. (ii) TITLE OF INVENTION:
(iii) NUMBER OF SEQUENCES: (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Societa Italiana Brevetti
(B) STREET: Piazza di Pietra, 39 (C) CITY: Rome
(D) COUNTRY: Italy
(E) POSTAL CODE: 1-00186 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk 3.5" 1.44 MBYTES (B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS Rev. 6.22
(D) SOFTWARE: Microsoft Word 6.0 (viii) ATTORNEY INFORMATION
(A) NAME: DI CERBO, Mario (Dr.)- (C) REFERENCE: RM/X88470/PC-DC
(ix) TELECOMMUNICATION INFORMATION
(A) TELEPHONE: 06/6785941
(B) TELEFAX: 06/6794692
(C) TELEX: 612287 ROPAT (1) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: no (v) FRAGMENT TYPE: internal (vii) IMMEDIATE SOURCE:
(A) SYNTHESIS: production as recombinant protein in eucariotic cells (ix) FEATURE:
(A) NAME: Asn230Asp - -
fC) IDENTIFICATION METHOD: Electrophoresis on a denaturing SDS/polyacrylamide gel
(D) OTHER INFORMATION: amino acid sequence of a mutant form of the interleukin 6 receptor from position 222 to position 236.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: lie Thr Val Thr Ala Val Ala Arg Asp Pro Arg Trp Leu Ser Val 1 5 10 15
(2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: no
(v) FRAGMENT TYPE: internal (vii) IMMEDIATE SOURCE:
(A) SYNTHESIS: production as recombinant protein in eucariotic cells (ix) FEATURE:
(A) NAME: Ala228Asp/Asn230Asp
(C) IDENTIFICATION METHOD: Electrophoresis on a denaturing SDS/polyacrylamide gel
(D) OTHER INFORMATION: amino acid sequence of a mutant form of the interleukin 6 receptor from position 222 to position 236.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: lie Thr Val Thr Ala Val Asp Arg Asp Pro Arg Trp Leu Ser Val 1 5 10 15 (3) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: no (v) FRAGMENT TYPE: internal (vii) IMMEDIATE SOURCE:
(A) SYNTHESIS: production as recombinant protein in eucariotic cells (ix) FEATURE: (A) NAME: His280Ser/Asp281Val
(C) IDENTIFICATION METHOD:Electrophoresis on a denaturing SDS/polyacrylamide gel
(D) OTHER INFORMATION: amino acid sequence of a mutant form of the interleukin 6 receptor from position 273 to position 287.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: Leu Gin His His Cys Val He Ser Val Ala Trp Ser Gly Leu Arg 1 5 10 15
(4) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 66 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: no
(v) FRAGMENT TYPE: internal (vii) IMMEDIATE SOURCE:
(A) SYNTHESIS: production as recombinant protein in eucariotic cells (ix) FEATURE:
(A) NAME: Ala228Asp/Asn230Asp/His280Ser/Asp281Val
(C) IDENTIFICATION METHOD:Electrophoresis on a denaturing SDS/polyacrylamide gel (D) OTHER INFORMATION: amino acid sequence of a mutant form of the interleukin 6 receptor from position 222 to position 287.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: He Thr Val Thr Ala Val Asp Arg Asp Pro Arg Trp Leu Ser Val T 1 5 10 15
Trp Gin Asp Pro His Ser Trp Asn Ser Ser Phe Tyr Arg Leu Arg P 20 25 30 Glu Leu Arg Tyr Arg Ala Glu Arg Ser Lys Thr Phe Thr Thr Trp Met
35 40 45
Val Lys Asp Leu Gin His His Cys Val He Ser Val Ala Trp Ser Gly 50 55 60 Leu Arg 65

Claims

1. Antagonist of interleukin-6 (IL-6), characterized in that it consists in soluble forms of the α receptor of IL-6 (sIL-6Rα) containing one or more mutations in the interface binding with gp 130.
2. Antagonist of interleukin-6 according to claim 1, in which sIL-6Rα contains at least one mutation in a position chosen from the group comprising Ala 228, Asn 230, His 280 and Asp 281.
3. Antagonist of interleukin 6 according to claim 1 or 2, in which sIL-6Rα contains the mutation Asn230Asp (SEQ ID NO: 1) .
4. Antagonist of interleukin 6 according to claim 1 or 2, in which sIL-6Rα contains the mutation Ala228Asp/Asn230/Asp (SEQ ID NO: 2) .
5. Antagonist of interleukin 6 according to claim 1 or 2, in which sIL-6Rα contains the mutations His280Ser/Asp281Val (SEQ ID NO: 3) .
6. Antagonist of interleukin 6 according to claim 1 or 2, in which sIL-6Rα contains the mutations
Ala228Asp/Asn230Asp/His280Ser/Asp281Val (SEQ ID NO: 4) .
7. Use of interleukin 6 antagonists according to claims 1 to 6, for the study and preparation of drugs capable of controlling, preventing and treating diseases caused by abnormal IL-6 activity.
8. Soluble receptors acting as IL-6 antagonists and their use, as described, illustrated and claimed above.
EP95940401A 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists Withdrawn EP0742794A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM940794 1994-12-06
ITRM940794A IT1274350B (en) 1994-12-06 1994-12-06 INTERLEUCHINA-6 (IL-6) ANTAGONISTS, WHICH CONSIST OF SOLUBLE FORMS OF THE ALFA RECEPTOR OF IL-6, CHANGED IN THE INTERFACE THAT LINKS TO GP 130
PCT/IT1995/000208 WO1996017869A2 (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists

Publications (1)

Publication Number Publication Date
EP0742794A1 true EP0742794A1 (en) 1996-11-20

Family

ID=11402851

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95940401A Withdrawn EP0742794A1 (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists

Country Status (7)

Country Link
EP (1) EP0742794A1 (en)
JP (1) JPH09503232A (en)
CN (1) CN1139933A (en)
AU (1) AU4186696A (en)
CA (1) CA2177837A1 (en)
IT (1) IT1274350B (en)
WO (1) WO1996017869A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
CA2230949C (en) * 1995-09-28 2009-11-17 Judith Chebath Synthetic peptides that inhibit il-6 activity
US6217858B1 (en) 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
GB9621095D0 (en) * 1996-10-09 1996-11-27 Imperial College Novel system
ES2312184T3 (en) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha THERAPEUTIC PREVENTIVE AGENTS FOR THE TREATMENT OF MULTIPLE SCLEROSIS, CONTAINING ANTI-RECEIVING ANTIBODIES OF IL-6 ANTAGONISTS.
US7227837B1 (en) 1998-04-30 2007-06-05 At&T Labs, Inc. Fault tolerant virtual tandem switch
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
JP4799516B2 (en) * 1998-08-24 2011-10-26 中外製薬株式会社 A prophylactic or therapeutic agent for pancreatitis comprising an IL-6 antagonist as an active ingredient
ES2276525T3 (en) 1998-08-24 2007-06-16 Chugai Seiyaku Kabushiki Kaisha PREVENTIVES OR REMEDIES FOR PANCREATITIS CONTAINING ANTI-RECEPTOR ANTIBODIES IL-6 AS ACTIVE INGREDIENT.
DE69937070D1 (en) * 1998-11-05 2007-10-18 Omeros Corp RINSE SOLUTION AND METHOD FOR PAIN LIFTING AND INFLAMMATION INHIBITION
WO2001016166A2 (en) 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AUPR769501A0 (en) * 2001-09-14 2001-10-11 Biomolecular Research Institute Limited Cytokine receptor 1
CN100340294C (en) 2003-02-24 2007-10-03 中外制药株式会社 Remedy for spinal injury containing interleukin-6 antagonist
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
NZ546557A (en) 2003-10-17 2010-01-29 Chugai Pharmaceutical Co Ltd Therapeutic agent for mesothelioma comprising interleukin-6
AR048210A1 (en) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd A PREVENTIVE AGENT FOR VASCULITIS.
WO2007043641A1 (en) 2005-10-14 2007-04-19 Fukuoka University Inhibitor of transplanted islet dysfunction in islet transplantation
BRPI0617664B8 (en) 2005-10-21 2021-05-25 Chugai Pharmaceutical Co Ltd use of an antibody recognizing IL-6 for the production of a pharmaceutical composition to treat myocardial infarction or suppress left ventricular remodeling after myocardial infarction
AR057582A1 (en) 2005-11-15 2007-12-05 Nat Hospital Organization AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
AR057941A1 (en) 2005-11-25 2007-12-26 Univ Keio THERAPEUTIC AGENTS FOR PROSTATE CANCER
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
CN101495146B (en) 2006-04-07 2012-10-17 国立大学法人大阪大学 Muscle regeneration promoter
TWI438208B (en) 2007-01-23 2014-05-21 Chugai Pharmaceutical Co Ltd Agents for suppressing chronic rejection reaction
KR101665729B1 (en) 2008-06-05 2016-10-12 국립연구개발법인 고쿠리츠간켄큐센터 Neuroinvasion inhibitor
DK2578231T3 (en) 2010-05-28 2022-12-12 Chugai Pharmaceutical Co Ltd ANTI-TUMOR T-CELL RESPONSE AMPLIFIER
WO2011149046A1 (en) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター Therapeutic agent for pancreatic cancer
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
TWI805046B (en) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Use of IL-6 receptor antibody for preparing pharmaceutical composition
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
WO2019151418A1 (en) 2018-01-31 2019-08-08 元一 加藤 Therapeutic agent for asthma containing il-6 inhibitor
JP7439372B2 (en) * 2018-06-21 2024-02-28 シャタック ラボ，インコーポレイテッド Heterodimeric proteins and their uses
JP7501876B2 (en) 2019-04-17 2024-06-18 国立大学法人広島大学 Treatment for urological cancer characterized by administering an IL-6 inhibitor and a CCR2 inhibitor in combination
CN110133241B (en) * 2019-05-21 2022-05-27 中国食品药品检定研究院 Novel method for measuring biological activity of recombinant human soluble gp130-Fc fusion protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3363463B2 (en) * 1991-10-02 2003-01-08 忠三 岸本 IL-6 receptor derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9617869A2 *

Also Published As

Publication number Publication date
CA2177837A1 (en) 1996-06-07
IT1274350B (en) 1997-07-17
CN1139933A (en) 1997-01-08
JPH09503232A (en) 1997-03-31
AU4186696A (en) 1996-06-26
WO1996017869A2 (en) 1996-06-13
ITRM940794A1 (en) 1996-06-06
ITRM940794A0 (en) 1994-12-06
WO1996017869A3 (en) 1996-08-29

Similar Documents

Publication Publication Date Title
WO1996017869A2 (en) Interleukin-6 (il-6) antagonists
RU2135584C1 (en) Homodimer p40 of interleukin-12
Hammacher et al. Structure‐function analysis of human IL‐6: identification of two distinct regions that are important for receptor binding
JP2657221B2 (en) Human Fcγ receptor III
EP0673420B1 (en) Mammalian receptors for interleukin-10 (il-10)
US6232446B1 (en) TNF ligands
CA2210644A1 (en) Ligands for eph-like receptors
JP2007267750A (en) Isolated nucleic acid molecules which encode soluble il-tif/il-22 receptor or binding protein which binds to il-tif/il-22, and uses thereof
CA2062975A1 (en) Antagonists of gm-csf derived from the carboxyl terminus
EP2292760A2 (en) Mammalian cytokines, receptors, related reagents and methods
EP0790305B1 (en) Mutant human growth hormones and their uses
WO1991008231A1 (en) [Ala IL-8]77 AS A LEUKOCYTE ADHESION INHIBITOR
JP3907661B2 (en) INTERFERON-α / β BINDING PROTEIN, PROCESS FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
US6171824B1 (en) Hybrid cytokines
JP2002512782A (en) G-CSF receptor agonist antibody and screening method thereof
Moritz et al. The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex
US6280975B1 (en) IL-6 mutein and DNA encoding thereto
EP0769055A1 (en) Variants of leukemia inhibitory factor
WO2004028555A1 (en) Resistin binding proteins, their preparation and use
CA2124338A1 (en) Region of cytoplasmic domain of the human interleukin-4 receptor, as antagonists of il-4
IL126484A (en) Il-6 mutein, its preparation and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19961114

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980701